var data={"title":"Penicillin, antistaphylococcal penicillins, and broad-spectrum penicillins","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"topicTitle\">Penicillin, antistaphylococcal penicillins, and broad-spectrum penicillins</div><dl id=\"topicContributors\"><dt><span> </span>Author:</dt><dd><a href=\"https://www.uptodate.com/contents/penicillin-antistaphylococcal-penicillins-and-broad-spectrum-penicillins/contributors\" class=\"contributor contributor_credentials\">Alyssa R Letourneau, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a href=\"https://www.uptodate.com/contents/penicillin-antistaphylococcal-penicillins-and-broad-spectrum-penicillins/contributors\" class=\"contributor contributor_credentials\">David C Hooper, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a href=\"https://www.uptodate.com/contents/penicillin-antistaphylococcal-penicillins-and-broad-spectrum-penicillins/contributors\" class=\"contributor contributor_credentials\">Allyson Bloom, MD</a></dd></dl><p class=\"disclosureLink\"><a href=\"https://www.uptodate.com/contents/penicillin-antistaphylococcal-penicillins-and-broad-spectrum-penicillins/contributor-disclosure\" class=\"contributor contributor_credentials\">Contributor Disclosures</a></p><div id=\"reviewProcess\"><span>All topics are updated as new evidence becomes available and our <a href=\"https://www.uptodate.com/home/editorial-policy\" target=\"_blank\" class=\"policy policy_editorialpolicy\">peer review process</a> is complete.</span></div><div id=\"literatureReviewDate\"><span class=\"emphasis\">Literature review current through:</span>&#160;Feb 2018.&#160;&#124;&#160;<span class=\"emphasis\">This topic last updated:</span>&#160;Jul 26, 2017.</div><div id=\"topicWhatsNewContainer\"></div><div id=\"topicText\"><p class=\"headingAnchor\" id=\"H1\"><span class=\"h1\">INTRODUCTION</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Beta-lactam antibiotics are among the most commonly prescribed drugs, grouped together based upon a shared structural feature, the beta-lactam ring. The classification, spectrum of activity and pharmacology of one group of beta-lactam antibiotics, the penicillins, will be reviewed here. The mechanisms of action and resistance and major adverse reactions of the beta-lactam antibiotics are discussed separately. (See <a href=\"topic.htm?path=beta-lactam-antibiotics-mechanisms-of-action-and-resistance-and-adverse-effects\" class=\"medical medical_review\">&quot;Beta-lactam antibiotics: Mechanisms of action and resistance and adverse effects&quot;</a>.) The cephalosporins and other beta-lactam drugs are also discussed separately. (See <a href=\"topic.htm?path=cephalosporins\" class=\"medical medical_review\">&quot;Cephalosporins&quot;</a> and <a href=\"topic.htm?path=combination-beta-lactamase-inhibitors-carbapenems-and-monobactams\" class=\"medical medical_review\">&quot;Combination beta-lactamase inhibitors, carbapenems, and monobactams&quot;</a>.) </p><p class=\"headingAnchor\" id=\"H2\"><span class=\"h1\">CLASSIFICATION</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Penicillins can be classified into the following categories:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><a href=\"topic.htm?path=penicillin-g-intravenous-and-short-acting-intramuscular-drug-information\" class=\"drug drug_general\">Penicillin G</a></p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Antistaphylococcal penicillins (<a href=\"topic.htm?path=nafcillin-drug-information\" class=\"drug drug_general\">nafcillin</a>, <a href=\"topic.htm?path=oxacillin-drug-information\" class=\"drug drug_general\">oxacillin</a>, <a href=\"topic.htm?path=cloxacillin-united-states-not-available-drug-information\" class=\"drug drug_general\">cloxacillin</a> and <a href=\"topic.htm?path=dicloxacillin-drug-information\" class=\"drug drug_general\">dicloxacillin</a>)</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Broad-spectrum penicillins: second generation (<a href=\"topic.htm?path=ampicillin-drug-information\" class=\"drug drug_general\">ampicillin</a>, <a href=\"topic.htm?path=amoxicillin-drug-information\" class=\"drug drug_general\">amoxicillin</a> and related agents), third generation (carbenicillin and ticarcillin) and fourth generation (<a href=\"topic.htm?path=piperacillin-united-states-not-available-drug-information\" class=\"drug drug_general\">piperacillin</a>)</p><p/><p class=\"headingAnchor\" id=\"H3\"><span class=\"h1\">SPECTRUM OF ACTIVITY</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>One of the major differences among the penicillins is the range of bacteria against which they are active.</p><p class=\"headingAnchor\" id=\"H4\"><span class=\"h2\">Penicillin G</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span><a href=\"topic.htm?path=penicillin-g-intravenous-and-short-acting-intramuscular-drug-information\" class=\"drug drug_general\">Penicillin G</a> is highly active against:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Gram-positive cocci (except penicillinase-producing staphylococci, penicillin-resistant pneumococci [<a href=\"https://www.uptodate.com/contents/penicillin-antistaphylococcal-penicillins-and-broad-spectrum-penicillins/abstract/1-5\" class=\"abstract_t\">1-5</a>], enterococci, and oxacillin-resistant staphylococci) (see <a href=\"topic.htm?path=resistance-of-streptococcus-pneumoniae-to-beta-lactam-antibiotics\" class=\"medical medical_review\">&quot;Resistance of Streptococcus pneumoniae to beta-lactam antibiotics&quot;</a>)</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Gram-positive rods such as <em>Listeria</em></p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Gram-negative cocci such as <em>Neisseria</em> spp (except penicillinase-producing <em>Neisseria</em>)</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Most anaerobes (with certain important exceptions, including <em>Bacteroides</em>)</p><p/><p><a href=\"topic.htm?path=penicillin-g-intravenous-and-short-acting-intramuscular-drug-information\" class=\"drug drug_general\">Penicillin G</a> is only bacteriostatic for enterococci; reports document strains with increasing intrinsic resistance to penicillin and, rarely, with high level resistance due to penicillinase production [<a href=\"https://www.uptodate.com/contents/penicillin-antistaphylococcal-penicillins-and-broad-spectrum-penicillins/abstract/6\" class=\"abstract_t\">6</a>] (see <a href=\"topic.htm?path=mechanisms-of-antibiotic-resistance-in-enterococci\" class=\"medical medical_review\">&quot;Mechanisms of antibiotic resistance in enterococci&quot;</a>). Serious infections with enterococci are generally treated with combination therapy of a cell wall active antibiotic such as penicillin, <a href=\"topic.htm?path=ampicillin-drug-information\" class=\"drug drug_general\">ampicillin</a>, or <a href=\"topic.htm?path=vancomycin-drug-information\" class=\"drug drug_general\">vancomycin</a> plus <a href=\"topic.htm?path=gentamicin-drug-information\" class=\"drug drug_general\">gentamicin</a> or <a href=\"topic.htm?path=streptomycin-drug-information\" class=\"drug drug_general\">streptomycin</a> (unless high level resistance to these aminoglycosides is present). Penicillin G is not active against Gram-negative bacilli because of poor penetration through the porin channel. (See <a href=\"topic.htm?path=beta-lactam-antibiotics-mechanisms-of-action-and-resistance-and-adverse-effects#H3\" class=\"medical medical_review\">&quot;Beta-lactam antibiotics: Mechanisms of action and resistance and adverse effects&quot;, section on 'Mechanisms of bacterial resistance'</a>.)</p><p class=\"headingAnchor\" id=\"H5\"><span class=\"h2\">Antistaphylococcal penicillins</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Antistaphylococcal penicillins (<a href=\"topic.htm?path=nafcillin-drug-information\" class=\"drug drug_general\">nafcillin</a>, <a href=\"topic.htm?path=oxacillin-drug-information\" class=\"drug drug_general\">oxacillin</a>, <a href=\"topic.htm?path=cloxacillin-united-states-not-available-drug-information\" class=\"drug drug_general\">cloxacillin</a> and <a href=\"topic.htm?path=dicloxacillin-drug-information\" class=\"drug drug_general\">dicloxacillin</a>) inhibit penicillinase-producing staphylococci but are inactive against oxacillin-resistant staphylococci [<a href=\"https://www.uptodate.com/contents/penicillin-antistaphylococcal-penicillins-and-broad-spectrum-penicillins/abstract/7\" class=\"abstract_t\">7</a>] (see <a href=\"topic.htm?path=methicillin-resistant-staphylococcus-aureus-mrsa-microbiology\" class=\"medical medical_review\">&quot;Methicillin-resistant Staphylococcus aureus (MRSA): Microbiology&quot;</a>). However, for strains of <em>Staphylococcus aureus</em> sensitive to oxacillin, antistaphylococcal penicillins are preferable to <a href=\"topic.htm?path=vancomycin-drug-information\" class=\"drug drug_general\">vancomycin</a> because vancomycin is less active against <em>S. aureus</em> than beta-lactams in in vitro and clinical studies [<a href=\"https://www.uptodate.com/contents/penicillin-antistaphylococcal-penicillins-and-broad-spectrum-penicillins/abstract/8\" class=\"abstract_t\">8</a>]. Antistaphylococcal penicillins have less intrinsic activity than <a href=\"topic.htm?path=penicillin-g-intravenous-and-short-acting-intramuscular-drug-information\" class=\"drug drug_general\">penicillin G</a> for bacteria susceptible to both, and antistaphylococcal penicillins are ineffective for enterococci, <em>Listeria</em>, and <em>Neisseria</em> spp.</p><p class=\"headingAnchor\" id=\"H6\"><span class=\"h2\">Broad-spectrum penicillins</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The broad-spectrum penicillins are distinguished by their activity against Gram-negative bacilli. These agents have been stratified into the second-generation penicillins (<a href=\"topic.htm?path=ampicillin-drug-information\" class=\"drug drug_general\">ampicillin</a>, <a href=\"topic.htm?path=amoxicillin-drug-information\" class=\"drug drug_general\">amoxicillin</a> and related agents), the third-generation penicillins (carbenicillin and ticarcillin), and the fourth-generation penicillin <a href=\"topic.htm?path=piperacillin-united-states-not-available-drug-information\" class=\"drug drug_general\">piperacillin</a>. None of the broad-spectrum penicillins is effective against penicillinase-producing staphylococci.</p><p class=\"headingAnchor\" id=\"H7\"><span class=\"h3\">Second generation</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span><a href=\"topic.htm?path=ampicillin-drug-information\" class=\"drug drug_general\">Ampicillin</a>, <a href=\"topic.htm?path=amoxicillin-drug-information\" class=\"drug drug_general\">amoxicillin</a>, and closely related antibiotics are able to penetrate the porin channel of Gram-negative bacteria but are not stable to beta-lactamases. These antibiotics are active against the majority of strains of <em>Escherichia coli</em>, <em>Proteus mirabilis</em>, <em>Salmonella</em>, <em>Shigella</em>, and <em>Haemophilus influenzae</em>. While a large percentage of encapsulated <em>H. influenzae</em> type b from the blood and cerebrospinal fluid (CSF) of children are beta-lactamase positive (and ampicillin resistant), a much lower percent of the non-type b isolates from adult patients with community-acquired pneumonia are beta-lactamase positive [<a href=\"https://www.uptodate.com/contents/penicillin-antistaphylococcal-penicillins-and-broad-spectrum-penicillins/abstract/9-11\" class=\"abstract_t\">9-11</a>].</p><p><a href=\"topic.htm?path=amoxicillin-drug-information\" class=\"drug drug_general\">Amoxicillin</a> and <a href=\"topic.htm?path=ampicillin-drug-information\" class=\"drug drug_general\">ampicillin</a> have an identical spectrum of activity, but amoxicillin is better absorbed from the intestine when administered orally and yields higher blood and urine levels. Amoxicillin is available generically and is preferable to ampicillin for oral use except in the therapy of <em>Shigella</em> infections sensitive to ampicillin. (See <a href=\"topic.htm?path=shigella-infection-treatment-and-prevention-in-adults\" class=\"medical medical_review\">&quot;Shigella infection: Treatment and prevention in adults&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H8\"><span class=\"h3\">Third generation</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Carbenicillin and ticarcillin also can penetrate the porin channel of Gram-negative bacteria in high doses but are less active than <a href=\"topic.htm?path=ampicillin-drug-information\" class=\"drug drug_general\">ampicillin</a> on a weight basis. However, the carboxy group on the side chain of these antibiotics expands the spectrum of activity by rendering them more resistant to the chromosomal beta-lactamases of certain organisms, such as indole-positive <em>Proteus</em> species, <em>Enterobacter</em> species, and <em>Pseudomonas</em> <em>aeruginosa</em>. Third and fourth generation penicillins are most useful in infections caused by these organisms.</p><p>Carbenicillin indanyl sodium is an orally absorbed form of carbenicillin which may be indicated for oral therapy of resistant urinary tract infections; the usual dose is one or two tablets (382 mg each) four times a day. Oral carbenicillin is not effective for therapy of infections outside of the urinary tract. Carbenicillin is not available for parenteral use in the United States.</p><p>Ticarcillin has the same spectrum of activity as carbenicillin but is two to four times more active on a weight basis against <em>P. aeruginosa</em>; the normal maximum parenteral dose is 18 <span class=\"nowrap\">g/day</span>. Ticarcillin is a disodium salt (which may cause a problem in patients with volume overload) and may cause a bleeding diathesis by inhibition of platelet function and prolongation of the bleeding time. Ticarcillin is administered now in combination with a beta-lactamase inhibitor. Ticarcillin and <a href=\"topic.htm?path=ticarcillin-and-clavulanate-potassium-united-states-not-available-drug-information\" class=\"drug drug_general\">ticarcillin-clavulanate</a> are no longer available in the United States. (See <a href=\"topic.htm?path=combination-beta-lactamase-inhibitors-carbapenems-and-monobactams#H2\" class=\"medical medical_review\">&quot;Combination beta-lactamase inhibitors, carbapenems, and monobactams&quot;, section on 'Beta-lactamase inhibitor combinations'</a>.)</p><p class=\"headingAnchor\" id=\"H9\"><span class=\"h3\">Fourth generation</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span><a href=\"topic.htm?path=piperacillin-united-states-not-available-drug-information\" class=\"drug drug_general\">Piperacillin</a> is a derivative of <a href=\"topic.htm?path=ampicillin-drug-information\" class=\"drug drug_general\">ampicillin</a>&nbsp;[<a href=\"https://www.uptodate.com/contents/penicillin-antistaphylococcal-penicillins-and-broad-spectrum-penicillins/abstract/12\" class=\"abstract_t\">12</a>]. It covers much the same spectrum as carbenicillin and ticarcillin but is more active in vitro on a weight basis. In addition, it has some activity against strains of <em>Klebsiella</em>, although cephalosporins remain the preferred agents. It is more active than carbenicillin or ticarcillin against enterococci and <em>Bacteroides fragilis</em>, but other agents are preferred for the treatment of these organisms as well.</p><p><a href=\"topic.htm?path=piperacillin-united-states-not-available-drug-information\" class=\"drug drug_general\">Piperacillin</a> is somewhat more active against Enterobacteriaceae than carbenicillin or ticarcillin and more active than ticarcillin against <em>P. aeruginosa</em>. As with ticarcillin, clinical failures have occurred when piperacillin is used as a single agent to treat serious <em>Pseudomonas</em> infections. Piperacillin is usually administered now in combination with a beta-lactamase inhibitor. (See <a href=\"topic.htm?path=combination-beta-lactamase-inhibitors-carbapenems-and-monobactams#H2\" class=\"medical medical_review\">&quot;Combination beta-lactamase inhibitors, carbapenems, and monobactams&quot;, section on 'Beta-lactamase inhibitor combinations'</a>.)</p><p class=\"headingAnchor\" id=\"H10\"><span class=\"h1\">PHARMACOLOGY</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The half-lives of the penicillins are similar and all achieve adequate levels in most bodily fluids, but dose adjustment with renal insufficiency depends upon the presence of non-renal routes of excretion and differs among these drugs.</p><p class=\"headingAnchor\" id=\"H11\"><span class=\"h2\">Half-life</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>All of the available penicillins have relatively short half-lives (generally one hour or less); all of the parenteral agents are usually administered on an every four hour basis when treating serious systemic infections in patients with normal renal function. <a href=\"topic.htm?path=piperacillin-united-states-not-available-drug-information\" class=\"drug drug_general\">Piperacillin</a> has dose-dependent pharmacokinetics and a longer half-life when higher doses are administered.</p><p class=\"headingAnchor\" id=\"H12\"><span class=\"h2\">Levels in different bodily fluids</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>All of the penicillins achieve therapeutic levels in pleural, pericardial, peritoneal and synovial fluids, as well as urine. All achieve levels in bile higher than corresponding serum levels (assuming the absence of obstruction); <a href=\"topic.htm?path=nafcillin-drug-information\" class=\"drug drug_general\">nafcillin</a>, <a href=\"topic.htm?path=ampicillin-drug-information\" class=\"drug drug_general\">ampicillin</a>, and <a href=\"topic.htm?path=piperacillin-united-states-not-available-drug-information\" class=\"drug drug_general\">piperacillin</a> achieve very high levels in bile.</p><p>The penicillins penetrate the CSF poorly in the absence of inflammation but achieve therapeutic levels in patients with meningitis who are given meningeal doses of parenteral therapy (<a href=\"image.htm?imageKey=ID%2F51256\" class=\"graphic graphic_table graphicRef51256 \">table 1</a>). (See <a href=\"topic.htm?path=initial-therapy-and-prognosis-of-bacterial-meningitis-in-adults#H11\" class=\"medical medical_review\">&quot;Initial therapy and prognosis of bacterial meningitis in adults&quot;, section on 'Drug entry into CSF'</a>.)</p><p class=\"headingAnchor\" id=\"H13\"><span class=\"h2\">Dose adjustment with renal insufficiency</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span><a href=\"topic.htm?path=nafcillin-drug-information\" class=\"drug drug_general\">Nafcillin</a>, <a href=\"topic.htm?path=oxacillin-drug-information\" class=\"drug drug_general\">oxacillin</a>, <a href=\"topic.htm?path=cloxacillin-united-states-not-available-drug-information\" class=\"drug drug_general\">cloxacillin</a>, and <a href=\"topic.htm?path=dicloxacillin-drug-information\" class=\"drug drug_general\">dicloxacillin</a> have major non-renal routes of clearance and need no dose modification even in the presence of severe renal failure. <a href=\"topic.htm?path=ampicillin-drug-information\" class=\"drug drug_general\">Ampicillin</a> and the structurally related antibiotic <a href=\"topic.htm?path=piperacillin-united-states-not-available-drug-information\" class=\"drug drug_general\">piperacillin</a>, require dose modification predominantly when the glomerular filtration rate (GFR) is below 10 <span class=\"nowrap\">mL/min</span>. Ticarcillin requires dose modification when the GFR is below 50 <span class=\"nowrap\">mL/min</span>.</p><p>The dosing (<a href=\"image.htm?imageKey=ID%2F63839\" class=\"graphic graphic_table graphicRef63839 \">table 2</a>) and adjustment of dose in the patient with renal dysfunction (<a href=\"image.htm?imageKey=ID%2F79502\" class=\"graphic graphic_table graphicRef79502 \">table 3</a>) of ticarcillin and <a href=\"topic.htm?path=piperacillin-united-states-not-available-drug-information\" class=\"drug drug_general\">piperacillin</a> are shown in the tables.</p><p class=\"headingAnchor\" id=\"H8071173\"><span class=\"h1\">SUMMARY</span></p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><a href=\"topic.htm?path=penicillin-g-intravenous-and-short-acting-intramuscular-drug-information\" class=\"drug drug_general\">Penicillin G</a> is highly active against most Gram-positive cocci, Gram-positive rods, Gram-negative cocci, and anaerobes. Exceptions are bacteria from these classes that have acquired resistance to penicillin as well as certain anaerobes that produce a beta-lactamase such as <em>Bacteroides</em>. Penicillin is only bacteriostatic against enterococci. (See <a href=\"#H4\" class=\"local\">'Penicillin G'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>For strains of <em>S. aureus</em> sensitive to <a href=\"topic.htm?path=oxacillin-drug-information\" class=\"drug drug_general\">oxacillin</a>, antistaphylococcal penicillins are preferable to <a href=\"topic.htm?path=vancomycin-drug-information\" class=\"drug drug_general\">vancomycin</a> because they are more active in vitro and in clinical studies. (See <a href=\"#H5\" class=\"local\">'Antistaphylococcal penicillins'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Broad-spectrum penicillins have increased activity over <a href=\"topic.htm?path=penicillin-g-intravenous-and-short-acting-intramuscular-drug-information\" class=\"drug drug_general\">penicillin G</a> against Gram-negative bacilli but are variably inactivated by beta-lactamases. (See <a href=\"#H6\" class=\"local\">'Broad-spectrum penicillins'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>All penicillins have relatively short half-lives and require frequent administration when given parenterally. CSF penetration is poor except in the presence of inflammation. The anti-staphylococcal penicillins need no dose modification when used in the setting of renal failure. (See <a href=\"#H10\" class=\"local\">'Pharmacology'</a> above.)</p></div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\"><li><a href=\"https://www.uptodate.com/contents/penicillin-antistaphylococcal-penicillins-and-broad-spectrum-penicillins/abstract/1\" class=\"nounderline abstract_t\">Tomasz A. Antibiotic resistance in Streptococcus pneumoniae. Clin Infect Dis 1997; 24 Suppl 1:S85.</a></li><li><a href=\"https://www.uptodate.com/contents/penicillin-antistaphylococcal-penicillins-and-broad-spectrum-penicillins/abstract/2\" class=\"nounderline abstract_t\">Friedland IR, McCracken GH Jr. Management of infections caused by antibiotic-resistant Streptococcus pneumoniae. N Engl J Med 1994; 331:377.</a></li><li><a href=\"https://www.uptodate.com/contents/penicillin-antistaphylococcal-penicillins-and-broad-spectrum-penicillins/abstract/3\" class=\"nounderline abstract_t\">Bradley JS, Scheld WM. The challenge of penicillin-resistant Streptococcus pneumoniae meningitis: current antibiotic therapy in the 1990s. Clin Infect Dis 1997; 24 Suppl 2:S213.</a></li><li><a href=\"https://www.uptodate.com/contents/penicillin-antistaphylococcal-penicillins-and-broad-spectrum-penicillins/abstract/4\" class=\"nounderline abstract_t\">Pallares R, Li&ntilde;ares J, Vadillo M, et al. Resistance to penicillin and cephalosporin and mortality from severe pneumococcal pneumonia in Barcelona, Spain. N Engl J Med 1995; 333:474.</a></li><li><a href=\"https://www.uptodate.com/contents/penicillin-antistaphylococcal-penicillins-and-broad-spectrum-penicillins/abstract/5\" class=\"nounderline abstract_t\">Whitney CG, Farley MM, Hadler J, et al. Increasing prevalence of multidrug-resistant Streptococcus pneumoniae in the United States. N Engl J Med 2000; 343:1917.</a></li><li><a href=\"https://www.uptodate.com/contents/penicillin-antistaphylococcal-penicillins-and-broad-spectrum-penicillins/abstract/6\" class=\"nounderline abstract_t\">Herman DJ, Gerding DN. Antimicrobial resistance among enterococci. Antimicrob Agents Chemother 1991; 35:1.</a></li><li><a href=\"https://www.uptodate.com/contents/penicillin-antistaphylococcal-penicillins-and-broad-spectrum-penicillins/abstract/7\" class=\"nounderline abstract_t\">Mulligan ME, Murray-Leisure KA, Ribner BS, et al. Methicillin-resistant Staphylococcus aureus: a consensus review of the microbiology, pathogenesis, and epidemiology with implications for prevention and management. Am J Med 1993; 94:313.</a></li><li><a href=\"https://www.uptodate.com/contents/penicillin-antistaphylococcal-penicillins-and-broad-spectrum-penicillins/abstract/8\" class=\"nounderline abstract_t\">Lowy FD. Staphylococcus aureus infections. N Engl J Med 1998; 339:520.</a></li><li><a href=\"https://www.uptodate.com/contents/penicillin-antistaphylococcal-penicillins-and-broad-spectrum-penicillins/abstract/9\" class=\"nounderline abstract_t\">Jorgensen JH, Doern GV, Maher LA, et al. Antimicrobial resistance among respiratory isolates of Haemophilus influenzae, Moraxella catarrhalis, and Streptococcus pneumoniae in the United States. Antimicrob Agents Chemother 1990; 34:2075.</a></li><li><a href=\"https://www.uptodate.com/contents/penicillin-antistaphylococcal-penicillins-and-broad-spectrum-penicillins/abstract/10\" class=\"nounderline abstract_t\">Heilmann KP, Rice CL, Miller AL, et al. Decreasing prevalence of beta-lactamase production among respiratory tract isolates of Haemophilus influenzae in the United States. Antimicrob Agents Chemother 2005; 49:2561.</a></li><li><a href=\"https://www.uptodate.com/contents/penicillin-antistaphylococcal-penicillins-and-broad-spectrum-penicillins/abstract/11\" class=\"nounderline abstract_t\">Geelen TH, Stassen FR, Hoogkamp-Korstanje JA, et al. Antimicrobial resistance among respiratory Haemophilus influenzae isolates from pulmonology services over a six-year period. Scand J Infect Dis 2013; 45:606.</a></li><li><a href=\"https://www.uptodate.com/contents/penicillin-antistaphylococcal-penicillins-and-broad-spectrum-penicillins/abstract/12\" class=\"nounderline abstract_t\">Bush LM, Johnson CC. Ureidopenicillins and beta-lactam/beta-lactamase inhibitor combinations. Infect Dis Clin North Am 2000; 14:409.</a></li></ol></div><div id=\"topicVersionRevision\">Topic 473 Version 13.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul id=\"innerOutline\"><li class=\"sr-button\"><a href=\"#H8071173\"><span>SUMMARY</span></a></li><li><a href=\"#H1\" id=\"outline-link-H1\">INTRODUCTION</a></li><li><a href=\"#H2\" id=\"outline-link-H2\">CLASSIFICATION</a></li><li><a href=\"#H3\" id=\"outline-link-H3\">SPECTRUM OF ACTIVITY</a><ul><li><a href=\"#H4\" id=\"outline-link-H4\">Penicillin G</a></li><li><a href=\"#H5\" id=\"outline-link-H5\">Antistaphylococcal penicillins</a></li><li><a href=\"#H6\" id=\"outline-link-H6\">Broad-spectrum penicillins</a><ul><li><a href=\"#H7\" id=\"outline-link-H7\">- Second generation</a></li><li><a href=\"#H8\" id=\"outline-link-H8\">- Third generation</a></li><li><a href=\"#H9\" id=\"outline-link-H9\">- Fourth generation</a></li></ul></li></ul></li><li><a href=\"#H10\" id=\"outline-link-H10\">PHARMACOLOGY</a><ul><li><a href=\"#H11\" id=\"outline-link-H11\">Half-life</a></li><li><a href=\"#H12\" id=\"outline-link-H12\">Levels in different bodily fluids</a></li><li><a href=\"#H13\" id=\"outline-link-H13\">Dose adjustment with renal insufficiency</a></li></ul></li><li><a href=\"#H8071173\" id=\"outline-link-H8071173\">SUMMARY</a></li><li><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"ID/473|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=ID/51256\" class=\"graphic graphic_table\">- CSF concentrations penicillins</a></li><li><a href=\"image.htm?imageKey=ID/63839\" class=\"graphic graphic_table\">- Dosing of ticarcillin and piperacillin</a></li><li><a href=\"image.htm?imageKey=ID/79502\" class=\"graphic graphic_table\">- Max doses ticarcillin and piperacillin in renal failure</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li class=\"plainItem\"><a href=\"topic.htm?path=beta-lactam-antibiotics-mechanisms-of-action-and-resistance-and-adverse-effects\" class=\"medical medical_review\">Beta-lactam antibiotics: Mechanisms of action and resistance and adverse effects</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=cephalosporins\" class=\"medical medical_review\">Cephalosporins</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=combination-beta-lactamase-inhibitors-carbapenems-and-monobactams\" class=\"medical medical_review\">Combination beta-lactamase inhibitors, carbapenems, and monobactams</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=initial-therapy-and-prognosis-of-bacterial-meningitis-in-adults\" class=\"medical medical_review\">Initial therapy and prognosis of bacterial meningitis in adults</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=mechanisms-of-antibiotic-resistance-in-enterococci\" class=\"medical medical_review\">Mechanisms of antibiotic resistance in enterococci</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=methicillin-resistant-staphylococcus-aureus-mrsa-microbiology\" class=\"medical medical_review\">Methicillin-resistant Staphylococcus aureus (MRSA): Microbiology</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=resistance-of-streptococcus-pneumoniae-to-beta-lactam-antibiotics\" class=\"medical medical_review\">Resistance of Streptococcus pneumoniae to beta-lactam antibiotics</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=shigella-infection-treatment-and-prevention-in-adults\" class=\"medical medical_review\">Shigella infection: Treatment and prevention in adults</a></li></ul></div></div>","javascript":null}